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Elderly patients treated with percutaneous coronary intervention (PCI) have a higher risk of both ischemic and 
bleeding complications than younger patients. However, few studies have reported how genetic information of 
elderly patients treated with PCI affects clinical outcomes. We investigated the impact of genetic variants on 
clinical outcomes in elderly patients. Correlations between single-nucleotide polymorphisms (CYP2C19 and 
P2Y12 receptor gene G52T polymorphism) and clinical outcomes were analyzed in 811 elderly patients (≥75 
years of age) from a prospective multicenter registry. The primary endpoint was a composite of myocardial 
infarction and death. Secondary endpoints were an individual event of death, cardiac death, myocardial 
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INTRODUCTION 
 
The number of elderly patients treated with 
percutaneous coronary intervention (PCI) for coronary 
artery disease is increasing [1, 2]. However, elderly 
patients who undergo PCI due to complex clinical 
conditions, such as comorbidities, show poor clinical 
outcomes [3, 4]. Elderly patients who undergo PCI have 
a higher risk of ischemic events and bleeding 
complications than younger patients and—
consequently—a higher mortality rate [5]. Numerous 
general population studies have been conducted on the 
optimal dual antiplatelet therapy (DAPT) strategy to 
reduce ischemic and bleeding risk [6]. In addition, a 
tailored DAPT strategy based on genetic variation has 
also been proposed [7–9]. However, few studies have 
addressed tailored DAPT based on genetic variation in 
elderly patients. This multicenter, prospective, 
observational study investigated the associations 
between genetic variants and clinical outcomes in 




Baseline characteristics and prevalence of genetic 
variants in elderly patients 
 
A total of 811 elderly patients (≥75 years of age) were 
enrolled in this study (Supplementary Figure 1 and 
Supplementary Table 1). The mean age was 79.1±3.6, 
and 53% were men. Index PCI due to acute coronary 
syndrome was performed in 452 (55.7%) patients, and 
132 (16.3%) patients had multivessel disease. A total of 
545 second-generation drug-eluting stents (DESs) with 
durable polymers were implanted in the enrolled 
patients (67.2%). In addition, third-generation DESs 
with biodegradable polymers were implanted in 27% of 
patients. Bare metal stents and first-generation DESs are 
rarely used (0.5%). The mean duration of DAPT 
(aspirin plus clopidogrel) was 321.4±89.5 days, and 
80% of patients maintained DAPT for >1 year. The 
prevalence of CYP2C19 and P2Y12 G52T variants was 
63% and 26%, respectively. CYP2C19 variants were 
classified into three groups according to their 
phenotypes: normal metabolizer (*1/*1), intermediate 
metabolizer (*1/*2 and *1/*3), and poor metabolizer 




According to the clinical pharmacogenetics 
implementation consortium guidelines for the 
CYP2C19 genotype [10], we classified the normal and 
intermediate metabolizers into one group and poor 
metabolizers into a second group. There were no 
statistically significant between-group differences in 
baseline characteristics, including the presentation of 
acute coronary syndrome and PRECISE-DAPT 
(Predicting Bleeding Complication in Patients 
Undergoing Stent Implantation and Subsequent Dual 
Antiplatelet Therapy) score (Table 1). The two groups 
had no significant differences in lesion characteristics 
and genetic variations (Supplementary Table 2). The 
two groups had similar discharge medications, without 
significant differences in in-hospital events. During the 
platelet function test, the poor metabolizers had a higher 
P2Y12 reaction unit (PRU) than the other group 
(269.9±82.8 vs. 234.0±74.8, respectively; p<0.001). 
However, no significant between-group differences 
were observed for DAPT duration (Supplementary 
Table 3). 
 
P2Y12 platelet adenosine 5′-diphosphate (ADP) 
receptor gene G52T polymorphism 
 
There were no statistical differences among the variants 
in baseline characteristics, including presentation of 
acute coronary syndrome, PRECISE-DAPT score, and 
genetic variations except history of hypertension (Table 
2 and Supplementary Table 4). However, The TT group 
of patients experienced significantly more in-hospital 
strokes (TT vs. GT vs. GG; 3.8% vs. 0.5% vs. 0.0%, 
p<0.001, respectively; Supplementary Table 5) and in-
hospital bleeding compared with the other group (19.2% 
vs. 2.1% vs. 4.5%, p=0.001; Supplementary Table 5) 
despite no significant between-group differences in 
discharge medications and PRU (254.2±60.8 vs. 
239.4±78.5 vs. 238.4±77.2, p=0.593). In addition, the 
overall duration of DAPT (346.5±39.1 vs. 324.4±89.4 
vs. 319.4±91.0, p=0.280) and the rate of DAPT 
infarction, stent thrombosis, target lesion revascularization, stroke, and major bleeding (Bleeding Academic 
Research Consortium ≥3). Regarding CYP2C19, patients with poor metabolizers had a significantly higher risk for 
the primary endpoint (hazard ratio [HR] 2.43; 95% confidence interval [95% CI] 1.12–5.24; p=0.024) and 
secondary endpoints (death and cardiac death). Regarding P2Y12 G52T, the TT group had a significantly higher 
occurrence of major bleeding than the other groups (HR 3.87; 95% CI 1.41–10.68; p=0.009). In conclusion, poor 
metabolizers of CYP2C19 and TT groups of P2Y12 G52T may be significant predictors of poor clinical outcomes 
in elderly patients. 
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Table 1. Baseline characteristics and genetic variation according to 
CYP2C19 variant in elderly patients. 
 
NM or IM PM 
p-value 
(n=694) (n=117) 
Male sex 376 (54.2%) 57 (48.7%) 0.320 
Age (years) 79.1±3.7 79.1±3.4 0.835 
Body-mass index (kg/m2)        23.7±3.4 23.7±3.1 0.978 
Current smoker 71 (10.2%) 16 (13.7%) 0.341 
Hypertension  508 (73.2%) 86 (73.5%) 1.000 
Diabetes mellitus     242 (34.9%) 36 (30.8%) 0.448 
Hypercholesterolemia 211 (30.4%) 41 (35.0%) 0.371 
Previous MI 46 (6.6%) 5 (4.3%) 0.444 
Previous PCI      106 (15.3%) 20 (17.1%) 0.715 
Previous CABG       9 (1.3%) 2 (1.7%) 1.000 
Previous CVA    75 (10.8%) 16 (13.7%) 0.453 
Congestive heart failure 44 (6.3%) 8 (6.8%) 1.000 
Chronic kidney disease  49 (7.1%) 4 (3.4%) 0.203 
Familial history of CAD  23 (3.3%) 5 (4.3%) 0.801 
Anemia 329 (47.4%) 53 (45.3%) 0.692 
Presentation with ACS 382 (55.0%) 70 (59.8%) 0.366 
PRECISE-DAPT score 25.9 ± 9.3 25.8 ± 10.3 0.889 
   - High risk 328 (47.3%) 50 (42.7%) 0.384 
P2Y12 G52T (rs6809699)   0.238 
   - GG  519 (74.8%) 79 (67.5%)  
   - GT 153 (22.0%) 34 (29.1%)  
   - TT   22 (3.2%) 4 (3.4%)  
Values are expressed as the number of patients (%) or mean (SD). ACS, acute 
coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery 
disease; CVA, cerebrovascular accident; IM, intermediate metabolizer; MI, 
myocardial infarction; NM, normal metabolizer; PCI, percutaneous coronary 
intervention; PM, poor metabolizer. 
maintenance for >1 year (85% vs. 83% vs. 78%, 





For CYP2C19, the primary endpoint, defined as the 
composite of myocardial infarction and death, was 
significantly higher in the poor metabolizer group than 
in the other group (PM vs NM or IM; 8.7% vs. 4.4%; 
Figure 1). Regarding the secondary endpoints, death 
and cardiac death were more common in the poor 
metabolizer group than in the other group. There were 
no differences in myocardial infarction, stent 
thrombosis, target lesion revascularization, stroke, or 
major bleeding between the two groups (Table 3). 
 
For the P2Y12 platelet ADP receptor gene G52T 
polymorphism, there were no significant differences in 
ischemic events, including primary endpoint between 
the groups (Table 4). However, the TT group had a 
significantly higher occurrence rate of major bleeding 
than the other groups (TT vs. GT vs. GG; 19.2% vs. 
4.9% vs. 5.4%; Figure 2). 
 
Genetic variation to adverse clinical outcome 
 
Poor metabolizers of CYP2C19 had a higher risk for the 
primary endpoint than the other group (hazard ratio 
[HR] 2.43; 95% confidence interval [95% CI] 1.12–
5.24; p=0.024; Figure 3). In addition, poor metabolizers 
were a prognostic factor of death (HR 2.63; 95% CI 
1.14–6.07; p=0.023; Figure 3) and cardiac death (HR 
2.95; 95% CI 1.12–7.73, p=0.028; Figure 3). Chronic 
kidney disease (HR 4.73; 95% CI 2.13–10.52, p<0.001) 
and current smoking (HR 2.62; 95% CI 1.08–6.34, 
p=0.033), and presentation with acute coronary 
syndrome (HR 2.60; 95% CI 1.17–5.81, p=0.020) were 
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Table 2. Baseline characteristics and genetic variation according to P2Y12 platelet adenosine 
5′-diphosphate receptor G52T polymorphism in elderly patients. 
 
GG GT TT 
p-value 
(N=598) (N=187) (N=26) 
Male sex 312 (52.2%) 110 (58.8%) 11 (42.3%) 0.145 
Age (years) 79.2±3.7 79.0±3.4 78.6±3.4 0.591 
Body-mass index (kg/m2)        23.8±3.5 23.5±3.1 23.6±2.3 0.424 
Current smoker 62 (10.4%) 22 (11.8%) 3 (11.5%) 0.857 
Hypertension  424 (70.9%) 150 (80.2%) 20 (76.9%) 0.039 
Diabetes mellitus     197 (32.9%) 71 (38.0%) 10 (38.5%) 0.406 
Hypercholesterolemia 177 (29.6%) 66 (35.3%) 9 (34.6%) 0.314 
Previous MI 33 (5.5%) 15 (8.0%) 3 (11.5%) 0.250 
Previous PCI      92 (15.4%) 32 (17.1%) 2 (7.7%) 0.453 
Previous CABG       7 (1.2%) 3 (1.6%) 1 (3.8%) 0.486 
Previous CVA    61 (10.2%) 27 (14.4%) 3 (11.5%) 0.277 
Congestive heart failure 36 (6.0%) 16 (8.6%) 0 (0.0%) 0.186 
Chronic kidney disease  40 (6.7%) 9 (4.8%) 4 (15.4%) 0.119 
Familial history of CAD  16 (2.7%) 11 (5.9%) 1 (3.8%) 0.110 
Anemia 283 (47.3%) 88 (47.1%) 11 (42.3%) 0.882 
Presentation with ACS 335 (56.0%) 104 (55.6%) 13 (50.0%) 0.832 
PRECISE-DAPT score 26.1 ± 9.7 25.3 ± 8.7 26.0 ± 9.2 0.564 
   - High risk 276 (46.2%) 89 (47.6%) 13 (50.0%) 0.541 
CYP2C19    0.268 
   - NM  224 (37.5%) 68 (36.4%) 6 (23.1%)  
   - IM 295 (49.3%) 85 (45.5%) 16 (61.5%)  
   - PM   79 (13.2%) 34 (18.2%) 4 (15.4%)  
Values are expressed as the number of patients (%) or mean (SD). ACS, acute coronary syndrome; CABG, 
coronary artery bypass graft; CAD, coronary artery disease; CVA, cerebrovascular accident; IM, 
intermediate metabolizer; MI, myocardial infarction; NM, normal metabolizer; PCI, percutaneous 
coronary intervention; PM, poor metabolizer. 
independent prognostic factors for the primary 
endpoint. Otherwise, a longer duration of DAPT 
resulted in more protective results (HR 0.991; 95% CI 
0.988–0.993, p<0.001). 
 
Regarding major bleeding, the TT variant of P2Y12 
G52T (HR 3.87, 95% CI 1.41–10.68, p=0.009; Figure 
3) and anemia (HR 2.39; 95% CI 1.24–4.61, p=0.009) 
were independent predictors. Meanwhile, poor 
metabolizers of the CYP2C19 variant was no statistical 





With the increasing rates of PCI in elderly patients, the 
increase in ischemic and bleeding events due to DAPT 
in this patient group needs to be addressed. However, 
the current guidelines offer little evidence on how to 
determine the optimal DAPT for the elderly [11, 12]. 
Moreover, studies on tailored DAPT based on genetic 
information in elderly patients are lacking. Our results 
suggest that identifying genetic variations in elderly 
patients helps guide DAPT treatment in this patient 
group undergoing PCI. 
 
The main findings of this study were as follows: 1) 
CYP2C19 and P2Y12 platelet ADP receptor gene G52T 
polymorphism affect clinical outcomes in elderly 
patients. 2) Regarding CYP2C19, the poor metabolizers 
had a higher risk of death, cardiac death, and composite 
events of myocardial infarction and death even after 
adjusting for other genetic and clinical variables. 3) 
Regarding P2Y12 G52T, the TT group had a higher risk 
of major bleeding when adjusting for other genetic and 
clinical variables. 
 
Loss-of-function CYP2C19 alleles decrease the active 
metabolites of clopidogrel in the blood, thereby 
reducing the inhibitory effect of clopidogrel on platelet 
aggregation [13]. Many studies have shown that loss-of-
function CYP2C19 alleles are associated with a higher 
risk of worse clinical outcomes [14–16]. In addition, the 
U.S. Food and Drug Administration reported a drug 
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safety concern for poor metabolizers of the CYP2C19 
variant [17]. However, routine genetic testing in clinical 
practice is excluded from the current guidelines. The 
Consortium Guidelines recommend different 
clopidogrel treatments for patients with loss-of-function 
CYP2C19 alleles [10]. Briefly, potent P2Y12 inhibitors, 
such as ticagrelor, are helpful in poor metabolizers. 
However, in the case of intermediate metabolizers or 
dose adjustment for clopidogrel, the results are 
controversial [18]. Moreover, few studies have been 
conducted on drug adjustment according to genetic 
variations in the elderly. Thus, we investigated the 
impact of CYP2C19 variants on clinical outcomes after 
PCI in elderly patients. 
 
This study showed that elderly patients with poor 
metabolizers, which require adjusting the antiplatelet 
therapy, had worse clinical outcomes than the normal 
and intermediate metabolizer groups when the same 
DAPT treatment (aspirin and clopidogrel) was applied. 
However, a longer duration of DAPT was protective 
against ischemic events in multivariate analysis, and 
there were no differences in major bleeding between the 




Figure 1. Time-to-event curves through 1-year for selected adverse events according to CYP2C19 variant. (A) Primary endpoint 
(myocardial infarction and death). (B) All-cause death. (C) Cardiac death. (D) Major bleeding (BARC≥3). PM, poor metabolizer; NM, normal 
metabolizer; IM, intermediate metabolizer. 
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Table 3. Cumulative incidence of clinical outcomes according to 
CYP2C19 variant in elderly patients. 
 NM or IM PM 
(n=694) (n=117) 
Primary endpoint 30 (4.4%) 10 (8.7%) 
Any Death 25 (3.7%) 9 (7.8%) 
Cardiac Death  17 (2.5%) 7 (6.1%) 
Myocardial infarction 7 (1.0%) 2 (1.7%) 
Stent thrombosis 7 (1.0%) 3 (2.6%) 
Target lesion revascularization 32 (4.6%) 6 (5.1%) 
Major bleeding 38 (5.5%) 8 (7.1%) 
Values are expressed as the number of patients (%: cumulative 
incidence). The primary endpoint was a composite of myocardial 
infarction and death. 
Table 4. Cumulative incidence of clinical outcomes according to P2Y12 
platelet adenosine 5′-diphosphate receptor G52T polymorphism in elderly 
patients. 
 GG GT TT 
(N=598) (N=187) (N=26) 
Primary endpoint 33 (5.4%) 6 (3.2%) 1 (4.0%) 
Any Death 27 (4.5%) 6 (3.2%) 1 (3.8%) 
Cardiac Death  20 (3.3%) 4 (2.1%) 0 (0.0%) 
Myocardial infarction 8 (1.3%) 1 (0.5%) 0 (0.0%) 
Stent thrombosis 7 (1.2%) 3 (1.6%) 0 (0.0%) 
Target lesion revascularization 25 (4.2%) 11 (5.9%) 2 (7.7%) 
Major bleeding 32 (5.4%) 9 (4.8%) 5 (19.2%) 
Values are expressed as the number of patients (%: cumulative incidence). The 
primary endpoint was a composite of myocardial infarction and death. 
dose of potent P2Y12 inhibitor replacement benefits 
poor metabolizers in elderly patients despite concern for 
maintaining a long duration of DAPT. 
 
Recent studies, including POPular Genetics and 
TAILOR-PCI, reported that a genotype-guided oral 
P2Y12 inhibitor strategy did not significantly reduce 
ischemic events compared with standard clopidogrel 
therapy in patients with CYP2C19 loss-of-function [8, 
19]. However, the risk of ischemic events in patients 
with DAPT increases with age [20]. Changes in platelet 
aggregation, which may contribute to increased 
ischemic events, increase as patient age increases, that 
is, a higher rate of ischemic events occurs due to 
increased platelet aggregability in the elderly [21]. 
Regarding the relationship between age and genomic 
variation, Dücker et al. [22] reported that systemic 
exposure might be increased in elderly patients, even if 
their old age affects pharmacokinetics and they share 
the same genetic polymorphism. The authors reported 
that additional systemic exposure of approximately 1.5-
fold occurred by age, even in the same poor metabolizer 
group, and more clinical events could occur [22]. This 
might explain why comparisons of clinical outcomes 
among the poor, normal, and intermediate metabolizers 
yielded negative results in the general population 
analysis [8, 23]. Our results revealed that worse clinical 
outcomes might occur in elderly patients who are poor 
metabolizers, as the platelet dysfunction caused by 
biological senescence from old age and the intrinsic risk 
factors caused by genetic polymorphisms interact with 
each other. The mechanism by which these interactions 
operate is not yet known, and further research is 
required. 
 
P2Y12, which is a G protein-coupled receptor, plays a 
crucial role in platelet aggregation and is activated by 
ADP [24, 25]. The P2Y12 receptor is a target of 
clopidogrel. The P2Y12 platelet ADP receptor gene 
G52T is one of the polymorphisms in exon 2 of the 
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Figure 2. Time-to-event curves through 1-year for selected adverse events according to P2Y12 G52T variant. (A) Major bleeding 




Figure 3. Adjusted multivariate risk of genetic variant in the elderly for subsequent one-year adverse events. (A) Poor 
metabolizer of CYP2C19 (B) TT of P2Y12 platelet adenosine 5′-diphosphate receptor gene G52T polymorphism. Hazard ratio was adjusted for 
sex, hypertension, diabetes mellitus, previous history of myocardial infarction, previous history of percutaneous coronary intervention, 
congestive heart failure, chronic kidney disease, current smoking status, anemia, clinical presentation to acute coronary syndrome, genomic 
variations (CYP2C19, P2Y12, PON1, and ABCB1), duration of dual antiplatelet therapy, multivessel involvement, minimal stent size, and total 
stent length. BARC, Bleeding Academic Research Consortium; HR, hazard ratio. 
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P2Y12 gene, as reported by Fontana [26]. Despite the 
low incidence in the TT group and a lack of evidence of 
the correlation between the TT variant and clinical 
outcomes, the TT variant was investigated as a potential 
marker of the P2Y12 gene. Recently, an association 
between the P2Y12 G52T variant and bleeding events 
has been reported [27]. Thus, we investigated the impact 
of P2Y12 G52T in elderly patients. Our results revealed 
that the risk of major bleeding was higher in the TT 
group than in the other groups. Patient who received 
DAPT in the TT group may have a higher probability of 
hemorrhage. Our results suggest that elderly patients 
with the TT variant benefit from adjusting the duration 
of DAPT to prevent major bleeding. 
 
Elderly patients have high ischemia and bleeding risks. 
The recent definition of the Academic Research 
Consortium for High Bleeding Risk (ARC-HBR) 
identifies advanced age (>75 years) as a bleeding risk 
factor [28, 29]. In addition, the PRECISE-DAPT score 
also includes age among the five items that predict 
bleeding risk [30, 31]. Thus, proper risk stratification 
for bleeding risk and ischemic risk for elderly patients 
should be conducted. As the aforementioned studies 
reviewed, the rate of bleeding risk based on the 
PRECISE-DAPT was high in this study, which was 
conducted for the elderly. The average PRECISE-
DAPT score of patients enrolled in this study was 
25.9±9.4, and 46.6% of patients were included in the 
high-risk cluster. However, we found no difference in 
the PRECISE-DAPT score and rate of the high-risk 
cluster according to CYP2C19 and P2Y12 variants; 
however, major bleeding events occurred frequently in 
the TT group. Thus, the probability of bleeding appears 
to vary according to gene variants, even in elderly 
patients. Thus, genotype testing might benefit elderly 
patients treated with DAPT after PCI. 
 
Although evidence-based studies in elderly patients are 
required, clinical trials in the elderly have not been 
conducted as often as in younger patients. Even in the 
current guidelines, the optimal DAPT for elderly 
patients is unclear because of numerous variables that 
potentially impact outcomes [11, 12]. A recent study 
reported changes in ischemia and bleeding in the elderly 
according to the duration of DAPT [32]. These results 
suggest that platelet function or genetic tests guided 
P2Y12 inhibitor adjustment may lead to better clinical 
outcomes in the elderly. To the best of our knowledge, 
our study is the first study to show that adjusting the 
treatment policy according to genetic variation among 
elderly patients undergoing PCI should be considered 
for better clinical outcomes. Importantly, our study 
revealed clinical outcomes after a year of follow-up 
after PCI. A longer-term investigation may provide 
insight into the clinical impact of the genotype 
according to clopidogrel maintenance or 
discontinuation. Since aspirin and clopidogrel were 
used as DAPT in this study, the impact on the clinical 
outcomes of the potent inhibitor ticagrelor is 
insufficient. Therefore, our results should be interpreted 
with caution. Finally, we cannot exclude the effects of 
other drugs, which were not investigated, that affect the 
metabolism of CYP2C19. 
 
In conclusion, in elderly patients who maintained 
standard DAPT after PCI, poor metabolizers of 
CYP2C19 had poor clinical outcomes regarding death 
and myocardial infarction. The TT group of P2Y12 
G52T had a higher risk of major bleeding. 
 




This subanalysis study included 811 elderly patients 
(≥75 years of age) from a prospective registry (GENIUS 
study, NCT02707445) (Supplementary Figure 1). The 
GENIUS study included 5000 patients who underwent 
PCI for coronary artery disease in 20 tertiary hospitals 
and investigated the influence of genotyping on 
coronary artery stenting outcomes between February 
2012 and July 2014. The inclusion criteria were as 
follows: 1) age >20 years and 2) all percutaneous 
coronary intervention patients within 1 month. Patients 
who had an allergy to aspirin or clopidogrel, pregnancy, 
or a life expectancy <1 year were excluded from this 
registry. Among the 5000 patients, 413 patients were 
excluded for various reasons, such as 
inclusion/exclusion criteria violation, follow-up loss, 
consent withdrawal, missing genotyping results, and 
missing platelet function test results. In addition, 98 
patients with rapid metabolizers (*17) in CYP2C19 
were excluded from the analysis because of their 
confounding effects [33]. Thus, among the 4489 
patients, 811 patients aged ≥75 years were defined as 
elderly patients. DAPT was recommended for a 
duration of 1 year (3 months) after the index PCI. 
DAPT included aspirin (100 mg daily) and clopidogrel 
(75 mg daily). Other P2Y12 inhibitors, such as 
ticagrelor and prasugrel, and anticoagulants were not 
prescribed after PCI. The study protocol was approved 
by the institutional review board of each participating 
center. Written informed consent was obtained from all 
patients at enrollment. This study complied with the 





Measured single nucleotide polymorphisms were 
CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), 
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CYP2C19*17 (rs12248560), ABCB1 (rs1045642), 
PON1 (rs662), and P2Y12 G52T (rs6809699). The 
genotype of each single nucleotide polymorphism was 
determined by pyrosequencing using a PSQ 96MA 
Pyrosequencer (Pyrosequencing AB, Uppsala, Sweden), 
as previously reported [34]. The results for ABCB1 and 
PON1 are described in the supplemental materials 
(Supplementary Figure 2 and Supplementary Tables 6, 
7). The VerifyNow P2Y12 assay (Accumetrics, San 
Diego, CA, USA) was used to measure the inhibitory 
effect of clopidogrel on platelet reactivity. The results 
are reported as PRUs. The residual platelet reactivity 





The primary endpoint were myocardial infarction and 
death. Secondary endpoints were an individual event of 
any death, cardiac death, myocardial infarction, stent 
thrombosis, target lesion revascularization, stroke, and 
major bleeding defined as the Bleeding Academic 




Between-group comparisons were performed using the 
independent Student’s t-test or analysis of variance for 
continuous variables and chi-square tests for categorical 
variables. Post hoc subgroup analysis was performed in 
accordance with the baseline characteristics. To 
estimate the effect of clinical outcomes, including 
myocardial infarction, death, cardiac death, stent 
thrombosis, target lesion revascularization, stroke, and 
major bleeding according to genetic variation, the HR 
was calculated using the Cox proportional hazards 
model. In the multivariate Cox regression analysis, HR 
was adjusted for sex, hypertension, diabetes mellitus, 
previous history of myocardial infarction, previous 
history of PCI, congestive heart failure, chronic kidney 
disease, current smoking status, anemia, clinical 
presentation to acute coronary syndrome (unstable 
angina, non-ST elevation myocardial infarction, and 
ST-elevation myocardial infarction), genetic variants 
(CYP2C19, P2Y12 G52T, PON1, and ABCB1), the 
duration of DAPT, multivessel involvement, minimal 
stent size, and total stent length. Two-tailed p-values 
were used, and p-values <0.05, were considered 
statistically significant. All analyses were performed 
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Supplementary Tables 
 
Supplementary Table 1. Baseline characteristics 
and genomic variation in elderly patients (≥75 




Age (years) 79.1±3.6 
Male sex 433 (53.3%) 
Body-mass index (kg/m2) 23.7±3.4 
Hypertension 594 (73.2%) 
Diabetes mellitus 278 (34.3%) 
Hypercholesterolemia 252 (31.1%) 
Previous MI 51 (6.3%) 
Previous PCI  126 (15.5%) 
Previous CABG  11 (1.4%) 
Previous CVA  91 (11.2%) 
Congestive heart failure 52 (6.4%) 
Chronic kidney disease  53 (6.5%) 
Familial history of CAD 28 (3.5%) 
Presentation with ACS            452 (55.7%) 
CYP2C19   
  - Normal metabolizer (*1/*1)             298 (36.7%) 
  - Intermediate metabolizer         396 (48.8%) 
     *1/*2                292 (36.0%) 
     *1/*3                104 (12.8%) 
  - Poor metabolizer            117 (14.4%) 
    *2/*2                66 (8.1%) 
    *2/*3                40 (4.9%) 
    *3/*3                11 (1.4%) 
P2Y12 G52T (rs6809699)  
  -  GG                598 (73.7%) 
  -  GT    187 (23.1%) 
  -  TT            26 (3.2%) 
Data are number of patients (%) or mean (SD). ACS, acute 
coronary syndrome; CABG, coronary artery bypass graft; 
CAD, coronary artery disease; CVA, cerebrovascular 
accident; PCI,  percutaneous coronary intervention. 
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Supplementary Table 2. Other genetic variations (PON1 and ABCB1) and lesion 
characteristics according to CYP2C19 variant in elderly patients (≥75 years of age). 
 
NM or IM PM 
p 
(N=694) (N=117) 
PON1                   0.738 
  - RR               266 (38.3%) 48 (41.0%)  
  - QR               353 (50.9%) 55 (47.0%)  
  - QQ               75 (10.8%) 14 (12.0%)  
ABCB1                  0.678 
  - CC               287 (41.4%) 44 (37.6%)  
  - CT               314 (45.2%) 58 (49.6%)  
  - TT               93 (13.4%) 15 (12.8%)  
Multivessel disease           111 (16.0%) 21 (17.9%) 0.693 
Left anterior descending artery            400 (57.6%) 79 (67.5%) 0.056 
Left circumflex artery 157 (22.6%) 26 (22.2%) 1.000 
Right coronary artery          250 (36.0%) 35 (29.9%) 0.240 
Left main            31 (4.5%) 7 (6.0%) 0.630 
Exist of visible thrombus 30 (4.3%) 5 (4.3%) 1.000 
Thrombosuction 33 (4.8%) 2 (1.7%) 0.210 
Number of stents         0.275 
  - 1                518 (74.6%) 82 (70.1%)  
  - 2                136 (19.6%) 25 (21.4%)  
  - 3 or over        40 (5.8%) 10 (8.6%)  
Number of lesions        1.4 ± 1.1 1.6 ± 1.3 0.197 
Minimal stent size     2.9 ± 0.4 2.8 ± 0.4 0.072 
Total length of stent      31.3 ± 17.6 33.4 ± 21.6 0.319 
Data are number of patients (%) or mean (SD). 
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Supplementary Table 3. In-hospital event, discharge medication, 
P2Y12 reaction unit, and dual antiplatelet therapy duration according 
to CYP2C19 variant in elderly patients (≥75 years of age). 
 
NM or IM PM 
P-value 
(N=694) (N=117) 
In-hospital event    
  Death 0 (0.0%) 1 (0.9%) 0.311 
  TLR    0 (0.0%) 0 (0.0%) - 
  Myocardial infarction 6 (0.9%) 0 (0.0%) 0.670 
  Stent thrombosis 0 (0.0%) 0 (0.0%) - 
  Stroke 2 (0.3%) 0 (0.0%) 1.000 
  Bleeding 30 (4.3%) 6 (5.1%) 0.882 
Discharge medication    
  Aspirin        690 (99.4%) 116 (99.1%) 1.000 
  Clopidogrel    685 (98.7%) 117 (100.0%) 0.446 
  Cilostazol     43 (6.2%) 10 (8.5%) 0.453 
  Proton pump inhibitor 147 (21.2%) 24 (20.5%) 0.967 
  CCB        196 (28.2%) 36 (30.8%) 0.653 
  Statin     646 (93.1%) 110 (94.0%) 0.863 
  ARB 270 (38.9%) 52 (44.4%) 0.303 
  ACEi     172 (24.8%) 26 (22.2%) 0.631 
  BB         402 (57.9%) 76 (65.0%) 0.184 
Platelet function test    
  VerifyNow PRU      234.0±74.8 269.9±82.8 <0.001 
  VerifyNow inhibition 25.0±25.6 17.7±38.2 0.049 
Duration of DAPT    
  Total duration (days) 322.7±87.1 313.7±103.0 0.373 
  >6 months 600 (86.5%) 99 (84.6%) 0.697 
  >12 months 569 (82.0%) 97 (82.9%) 0.913 
Data are number of patients (%) or mean (SD). ACEi, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta blocker; CCB, 
calcium channel blocker; DAPT, dual antiplatelet therapy; IM, intermediate 
metabolizer; NM, normal metabolizer; PM, poor metabolizer;   PRU, P2Y12 
reaction unit; TLR, target lesion revascularization. 
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Supplementary Table 4. Other genetic variations (PON1 and ABCB1) and lesion characteristics 
according to P2Y12 G52T polymorphism in elderly patients (≥75 years of age). 
 
GG GT TT 
p 
(N=598) (N=187) (N=26) 
PON1                    0.486 
  - RR               231 (38.6%) 71 (38.0%) 12 (46.2%)  
  - QR               304 (50.8%) 95 (50.8%) 9 (34.6%)  
  - QQ               63 (10.5%) 21 (11.2%) 5 (19.2%)  
ABCB1                   0.881 
  - CC               245 (41.0%) 75 (40.1%) 11 (42.3%)  
  - CT               276 (46.2%) 86 (46.0%) 10 (38.5%)  
  - TT               77 (12.9%) 26 (13.9%) 5 (19.2%)  
Multivessel disease           91 (15.2%) 39 (20.9%) 2 (7.7%) 0.092 
Left anterior descending artery            355 (59.4%) 107 (57.2%) 17 (65.4%) 0.699 
Left circumflex artery 128 (21.4%) 47 (25.1%) 8 (30.8%) 0.338 
Right coronary artery          204 (34.1%) 78 (41.7%) 3 (11.5%) 0.006 
Left main            29 (4.8%) 9 (4.8%) 0 (0.0%) 0.517 
Exist of visible thrombus 30 (5.0%) 3 (1.6%) 2 (7.7%) 0.093 
Thrombosuction 30 (5.0%) 3 (1.6%) 2 (7.7%) 0.093 
Number of stents          0.793 
  - 1                451 (75.4%) 129 (69.0%) 20 (76.9%)  
  - 2                111 (18.6%) 45 (24.1%) 5 (19.2%)  
  - 3 or over        36 (6.0%) 13 (6.9%) 1 (3.9%)  
Number of lesions        1.5 ± 1.2 1.4 ± 0.9 1.1 ± 0.3 0.285 
Minimal stent size     2.9 ± 0.4 2.9 ± 0.4 2.9 ± 0.3 0.750 
Total length of stent      31.0 ± 17.5 34.0 ± 20.5 29.9 ± 16.0 0.125 
Data are number of patients (%) or mean (SD). 
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Supplementary Table 5. In-hospital event, discharge medication, P2Y12 reaction 
unit, and dual antiplatelet therapy duration according to P2Y12 G52T polymorphism 
in elderly patients (≥75 years of age). 
 
GG GT TT 
P-value 
(N=598) (N=187) (N=26) 
In-hospital event     
  Death 1 (0.2%) 0 (0.0%) 0 (0.0%) 0.837 
  TLR    0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Myocardial infarction 5 (0.8%) 1 (0.5%) 0 (0.0%) 0.828 
  Stent thrombosis 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Stroke 0 (0.0%) 1 (0.5%) 1 (3.8%) <0.001 
  Bleeding 27 (4.5%) 4 (2.1%) 5 (19.2%) <0.001 
Discharge medication     
  Aspirin        593 (99.2%) 187 (100.0%) 26 (100.0%) 0.408 
  Clopidogrel    591 (98.8%) 185 (98.9%) 26 (100.0%) 0.854 
  Cilostazol      36 (6.0%) 14 (7.5%) 3 (11.5%) 0.449 
  Proton pump inhibitor 129 (21.6%) 35 (18.7%) 7 (26.9%) 0.536 
  CCB        169 (28.3%) 53 (28.3%) 10 (38.5%) 0.528 
  Statin     556 (93.0%) 175 (93.6%) 25 (96.2%) 0.799 
  ARB 239 (40.0%) 73 (39.0%) 10 (38.5%) 0.966 
  ACEi       145 (24.2%) 50 (26.7%) 3 (11.5%) 0.236 
  BB         352 (58.9%) 107 (57.2%) 19 (73.1%) 0.305 
Platelet function test     
  VerifyNow PRU      238.4±77.2 239.4±78.5 254.2±60.8 0.593 
  VerifyNow inhibition 24.4±30.2 23.6±20.5 16.5±15.5 0.363 
Duration of DAPT     
  Total duration (days) 319.4±91.0 324.4±89.4 346.5±39.1 0.280 
  > 6 months 506 (84.6%) 163 (87.2%) 25 (96.2%) 0.203 
  > 12 months 467 (78.1%) 156 (83.4%) 22 (84.6%) 0.233 
Data are number of patients (%) or mean (SD). ACEi, angiotensin-converting-enzyme inhibitor; 
ARB, angiotensin II receptor blocker; BB, beta blocker; CCB, calcium channel blocker; DAPT, 
dual antiplatelet therapy; PRU, P2Y12 reaction unit; TLR, target lesion revascularization. 
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Supplementary Table 6. Clinical presentation, duration of DAPT, PRU, and in-
hospital event according to PON1 variant. 
 
RR QR QQ 
p 
(N=314) (N=408) (N=89) 
Presentation with ACS 177 (56.4%) 222 (54.4%) 53 (59.6%) 0.649 
Duration of DAPT     
  Total duration (days) 329.4 ± 78.0 315.2 ± 98.1 322.2 ± 85.3 0.106 
  > 12 months 259 (82.5%) 315 (77.2%) 71 (79.8%) 0.219 
Platelet function test     
  VerifyNow PRU 237.5 ± 81.3 239.3 ± 74.2 244.6 ± 74.5 0.743 
In-hospital event     
  Death 0 (0.0%) 1 (0.2%) 0 (0.0%) 0.610 
  TLR 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Myocardial infarction 3 (1.0%) 2 (0.5%) 1 (1.1%) 0.696 
  Stent thrombosis 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Stroke 0 (0.0%) 2 (0.5%) 0 (0.0%) 0.372 
  Bleeding 11 (3.5%) 20 (4.9%) 5 (5.6%) 0.564 
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; TLR, target lesion 
revascularization; PRU, P2Y12 reaction unit. 
Supplementary Table 7. Clinical presentation, duration of DAPT, PRU, and in-
hospital event according to ABCB1 variant. 
 
CC CT TT 
p 
(N=331) (N=372) (N=108) 
Presentation with ACS 175 (52.9%) 212 (57.0%) 65 (60.2%) 0.332 
Duration of DAPT     
  Total duration (days) 320.0 ± 88.9 321.9 ± 92.3 324.3 ± 82.4 0.902 
  > 12 months 258 (77.9%) 302 (81.2%) 85 (78.7%) 0.554 
Platelet function test     
  VerifyNow PRU 239.2 ± 75.6 242.5 ± 77.3 227.5 ± 79.6 0.205 
In-hospital event     
  Death 0 (0.0%) 1 (0.3%) 0 (0.0%) 0.554 
  TLR 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Myocardial infarction 3 (0.9%) 2 (0.5%) 1 (0.9%) 0.826 
  Stent thrombosis 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
  Stroke 1 (0.3%) 1 (0.3%) 0 (0.0%) 0.854 
  Bleeding 15 (4.5%) 15 (4.0%) 6 (5.6%) 0.791 
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; TLR, target lesion 
revascularization; PRU, P2Y12 reaction unit. 
